Truist Securities Reiterates Buy on Roivant Sciences, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Roivant Sciences (NASDAQ:ROIV) and maintained a price target of $23.
September 26, 2023 | 4:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences has received a reiterated 'Buy' rating from Truist Securities, with a maintained price target of $23.
The reiterated 'Buy' rating from Truist Securities indicates a positive outlook for Roivant Sciences. The maintained price target of $23 suggests that the analyst believes the stock has potential for growth. This could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100